secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0000950170-23-009221
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion reports $44.1M net loss in 2022; cash $13.4M; evaluating options for zagociguat
--------------------------------------------------------------------------------

- Cash, equivalents & restricted cash $13.4M at Dec 31, 2022, down from $20.4M at Sep 30, 2022.
- Net loss $44.1M for FY 2022 vs $51.6M in FY 2021; R&D spend $31.5M, G&A $14.5M.
- Met with FDA in Q4 2022; filed for Orphan Drug Designation for zagociguat in MELAS.
- Refined Phase 2b design for zagociguat; manufactured drug product to support the study.
- Company actively evaluating capital, capabilities, or transactions to advance pipeline and maximize value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000095017023009221/0000950170-23-009221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000095017023009221/cycn-20230322.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer